MACH7 TECHNOLOGIES LIMITED (M7T)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

M7T

M7T - MACH7 TECHNOLOGIES LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.95
Index:

Mach7 Technologies develops software platforms for the healthcare industry. It specialises in image management systems and patient data management. The company has been listed on the ASX since 2005.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.30

25 Jun
2026

-0.005

OPEN

$0.31

-1.64%

HIGH

$0.31

171,049

LOW

$0.30

TARGET
$0.44 46.7% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . IDX . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
M7T: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 3.8 - 2.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-3.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx27.9 M
Book Value Per Share xxxxxxxxxxxxxxx14.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-1.3 M
Net Profit Margin xxxxxxxxxxxxxxx-31.99 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-22.28 %
Return on Invested Capital xxxxxxxxxxxxxxx-22.03 %
Return on Assets xxxxxxxxxxxxxxx-15.57 %
Return on Equity xxxxxxxxxxxxxxx-22.28 %
Return on Total Capital xxxxxxxxxxxxxxx-18.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx4 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx20 M
Price To Book Value xxxxxxxxxxxxxxx1.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.9 M
Capex % of Sales xxxxxxxxxxxxxxx3.28 %
Cost of Goods Sold xxxxxxxxxxxxxxx30 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

27/04/2026

1

Buy

$0.44

46.67%

Mach7 Technologies reported a downgrade to FY26 revenue guidance, with revenue now expected to be $28.6m and around -15% below FY25, as delays to sales in the Middle East are anticipated, offset by operating cost reductions.

Morgans found the optics around the downgrade rather negative but also not surprising given geopolitical tensions. Forecasts are moderated for the near term.

On a positive note, a lower operating cost base implies stronger operating leverage from FY27. Target is reduced to $0.44 from $0.76. A Buy rating is maintained.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.00 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -2.80 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

13/05/2026

3

Downgrade to Hold from Buy

$0.27

-10.00%

Canaccord Genuity downgrades Mach7 Technologies to a Hold rating from Buy and lowers the target price to $0.27 from $0.80.

The broker notes the company has entered a strategic reset following recent management transitions, with visibility into the path toward cash flow breakeven remaining limited.

Revenue forecasts have been revised down by -23% to -28% for FY26-FY28 to reflect delayed conversion of large capital deals and a headwind from AUD:USD exchange rate movements.

Operating cash flow is projected to remain a negative outflow until FY29, while cost-reduction measures implemented by the new leadership may exacerbate challenges in sales execution and service delivery.

Normalised EBITDA estimates have been materially impaired due to a weaker revenue mix and a flat near-term growth trajectory, according to the report.
Access Extra Coverage Research History >

M7T STOCK CHART

FNArena News on M7T

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia